In September 2025, we brought together senior leaders across business development, commercial strategy and HEOR for an in-depth roundtable on one of the most pressing questions facing early-stage biotechs: what does it truly mean to build for value in phase 1 and 2?

With investors, partners and analysts scrutinising access, differentiation and long-term viability much earlier than before, the group explored how early teams can make better decisions despite limited resources and rising expectations.

This white paper distils the insights from that discussion, highlighting where value is created or lost in early development and what leaders can do to improve outcomes. It offers a grounded view of how experienced leaders are approaching these challenges and what can help organisations make more informed early-stage decisions.

Navigating the early stages of biotech development is fraught with challenges and opportunities. For preclinical or clinical-stage biotech companies, having the right Chief Business Officer can be the difference between success and stagnation. This article explores the critical timing and reasons for hiring a skilled CBO, whether on a permanent or fractional basis, and how they can propel your biotech company forward.